Inactive Instrument

Highlights AEON Biopharma, Inc. Nasdaq

Equities

AEON

US00775E1029

Real-time Estimate Cboe BZX Other stock markets 09:53:00 17/05/2024 pm IST			5-day change	1st Jan Change
1.545 ^USD	0.00%		0.00%	0.00%

09/05	AEON Biopharma, Inc. Provides Update on Development Pipeline	CI
03/05	US Equity Markets Close Higher Friday Following Weak Jobs Report	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AEON Biopharma, Inc. Provides Update on Development Pipeline	09/05	CI
US Equity Markets Close Higher Friday Following Weak Jobs Report	04/05	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	04/05	MT
Sector Update: Health Care	04/05	MT
Top Midday Decliners	04/05	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	03/05	MT
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial	03/05	MT
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine	03/05	CI
Sector Update: Health Care Stocks Slide Late Afternoon	02/04	MT
Sector Update: Health Care	02/04	MT
AEON Biopharma Shares Tumble on Wider Q4 Loss	02/04	MT
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	30/03	CI
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	20/03	CI
AEON Biopharma, Inc. Presents Positive Clinical and Pre-Clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, At TOXINS 2024	19/01	CI
AEON Biopharma, Inc. Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	12/12	CI
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
AEON Biopharma, Inc. Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	20/23/20	CI
AEON Biopharma, Inc. Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia At the International Parkinson and Movement Disorders Society Congress®	29/23/29	CI
AEON Biopharma Gets Notice of Allowance for Soon-to-Issue US Patent Covering Its Migraine Treatment Candidate	24/23/24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AEON Biopharma, Inc. Nasdaq

Equities

AEON

US00775E1029

Highlights

Filters